AU2016275030B2 - Modified NK-92 cells for treating cancer - Google Patents

Modified NK-92 cells for treating cancer Download PDF

Info

Publication number
AU2016275030B2
AU2016275030B2 AU2016275030A AU2016275030A AU2016275030B2 AU 2016275030 B2 AU2016275030 B2 AU 2016275030B2 AU 2016275030 A AU2016275030 A AU 2016275030A AU 2016275030 A AU2016275030 A AU 2016275030A AU 2016275030 B2 AU2016275030 B2 AU 2016275030B2
Authority
AU
Australia
Prior art keywords
cells
cell
monoclonal antibody
seq
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016275030A
Other languages
English (en)
Other versions
AU2016275030A1 (en
Inventor
Tien Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunitybio Inc
Original Assignee
Immunitybio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunitybio Inc filed Critical Immunitybio Inc
Publication of AU2016275030A1 publication Critical patent/AU2016275030A1/en
Application granted granted Critical
Publication of AU2016275030B2 publication Critical patent/AU2016275030B2/en
Assigned to IMMUNITYBIO, INC. reassignment IMMUNITYBIO, INC. Request to Amend Deed and Register Assignors: NANTKWEST, INC.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/35—Cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4224—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4261—Proteoglycans, e.g. glypican, brevican or CSPG4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/11—Antigen recognition domain
    • A61K2239/13—Antibody-based
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
    • A61K2239/28—Expressing multiple CARs, TCRs or antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/04—Fusion polypeptide containing a localisation/targetting motif containing an ER retention signal such as a C-terminal HDEL motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2016275030A 2015-06-10 2016-06-10 Modified NK-92 cells for treating cancer Active AU2016275030B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562173701P 2015-06-10 2015-06-10
US62/173,701 2015-06-10
US201662337044P 2016-05-16 2016-05-16
US62/337,044 2016-05-16
PCT/US2016/036991 WO2016201304A1 (en) 2015-06-10 2016-06-10 Modified nk-92 cells for treating cancer

Publications (2)

Publication Number Publication Date
AU2016275030A1 AU2016275030A1 (en) 2017-12-14
AU2016275030B2 true AU2016275030B2 (en) 2021-12-09

Family

ID=57504144

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016275030A Active AU2016275030B2 (en) 2015-06-10 2016-06-10 Modified NK-92 cells for treating cancer

Country Status (10)

Country Link
US (3) US10738279B2 (enExample)
EP (3) EP4424326A3 (enExample)
JP (4) JP2018517415A (enExample)
KR (4) KR102526538B1 (enExample)
CN (2) CN113502270B (enExample)
AU (1) AU2016275030B2 (enExample)
CA (1) CA2987290C (enExample)
ES (1) ES2958720T3 (enExample)
IL (3) IL328383A (enExample)
WO (1) WO2016201304A1 (enExample)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201808811QA (en) 2014-04-10 2018-11-29 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Method and compositions for cellular immunotherapy
EP3805371A1 (en) 2014-05-15 2021-04-14 National University of Singapore Modified natural killer cells and uses thereof
ES2958720T3 (es) * 2015-06-10 2024-02-13 Immunitybio Inc Células NK-92 modificadas para tratar el cáncer
MX2018001568A (es) 2015-08-07 2019-04-25 Seattle Children´S Hospital Dba Seattle Children´S Res Institute Celulas t biespecificas de receptor quimerico de antigeno (car) para focalizacion a tumores solidos.
CN118652336A (zh) 2016-06-08 2024-09-17 普瑞赛格恩公司 Cd33特异性嵌合抗原受体
CN110168078B (zh) * 2017-01-06 2024-05-14 免疫生物公司 具有降低的cd96/tigit表达的遗传修饰的nk-92细胞
CA3049652A1 (en) * 2017-01-10 2018-07-19 Intrexon Corporation Modulating expression of polypeptides via new gene switch expression systems
CA3051866A1 (en) * 2017-02-01 2018-08-09 Nant Holdings Ip, Llc Calreticulin-mediated cancer treatment
AU2018220734B2 (en) * 2017-02-20 2025-03-06 Dragonfly Therapeutics, Inc. Proteins binding CD33, NKG2D and CD16
AU2018231193B2 (en) 2017-03-08 2021-07-22 Immunitybio, Inc. Modified NK-92 haNK003 cells for the clinic
BR112019018915A2 (pt) 2017-03-15 2020-04-14 Pandion Therapeutics Inc imunotolerância direcionada
CA3058144A1 (en) * 2017-03-27 2018-10-04 Nantcell, Inc. Ank and il-12 compositions and methods
CN117363636A (zh) 2017-03-27 2024-01-09 新加坡国立大学 一种编码嵌合受体的多核苷酸
MX2019011570A (es) 2017-03-27 2019-11-18 Nat Univ Singapore Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales.
KR102009040B1 (ko) * 2017-04-05 2019-08-08 한국생명공학연구원 Nk 세포 활성화 융합 단백질, nk 세포 및 이들을 포함하는 약제학적 조성물
KR20190141695A (ko) * 2017-04-13 2019-12-24 센티 바이오사이언시스, 인코포레이티드 병용 암 면역요법
AU2018273914A1 (en) 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance
TWI676483B (zh) * 2017-08-06 2019-11-11 強普生技股份有限公司 醫藥套組及其用途
KR102742741B1 (ko) 2017-10-18 2024-12-16 프레시전 인코포레이티드 스페이서를 포함하는 폴리펩타이드 조성물
WO2019084234A1 (en) * 2017-10-26 2019-05-02 St. Jude Childen's Research Hospital, Inc. METHODS AND COMPOSITIONS FOR TREATING CD33 + CANCERS AND IMPROVING IN VIVO PERSISTENCE OF CHIMERIC ANTIGEN RECEPTOR T CELLS
US20210187024A1 (en) * 2017-11-01 2021-06-24 Nantkwest, Inc. NK-92 Cells to Stimulate Anti-Cancer Vaccine
US20200392458A1 (en) * 2017-11-24 2020-12-17 Onk Therapeutics Limited Modified natural killer cells and natural killer cell lines targetting tumour cells
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
WO2019127215A1 (en) * 2017-12-28 2019-07-04 Nanjing Legend Biotech Co., Ltd. Multispecific chimeric receptors comprising an nkg2d domain and methods of use thereof
CN110028589B (zh) * 2018-02-07 2023-07-21 阿思科力(苏州)生物科技有限公司 嵌合抗原受体、表达该嵌合抗原受体的nkg2d car-nk细胞及其制备方法和应用
JP7360174B2 (ja) 2018-02-09 2023-10-12 ナショナル ユニヴァーシティー オブ シンガポール ナチュラルキラー細胞免疫療法における活性化キメラ受容体及びその使用
CN112004829A (zh) * 2018-03-12 2020-11-27 南克维斯特公司 Cd33car修饰的高亲和力nk细胞(t-hank)用于降低髓系衍生的抑制细胞的抑制活性(或降低对nk细胞活性的负面影响)的用途
WO2019182425A1 (ko) * 2018-03-23 2019-09-26 주식회사 에스엘바이젠 신규 키메라 항원 수용체 암호화 유전자가 형질도입된 유전자 변형 nk 세포주 및 그의 용도
US12441787B2 (en) 2018-04-02 2025-10-14 National University Of Singapore Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
IL321548A (en) 2018-05-22 2025-08-01 Immunitybio Inc Recombinant NK cells expressing a chimeric antigen receptor (CAR) for epsilon-FC and uses thereof
KR102907902B1 (ko) * 2018-08-01 2026-01-02 난트퀘스트, 인크. 면역 요법의 안정한 유전적 변형을 위한 귀소 수용체 또는 사이토카인, 및 키메라 항원 수용체를 포함하는 4 시스트론 시스템
WO2020028654A1 (en) 2018-08-01 2020-02-06 Nantkwest, Inc. Combined invasion and cytotoxicity assay using chemokine secreting target cells
WO2020044239A1 (en) 2018-08-29 2020-03-05 National University Of Singapore A method to specifically stimulate survival and expansion of genetically-modified immune cells
KR20240162586A (ko) * 2018-10-31 2024-11-15 난트퀘스트, 인크. Pd-l1 키메라 항원 수용체-발현 nk 세포에 의한 pd-l1-양성 악성종양의 제거
KR20200119892A (ko) * 2018-10-31 2020-10-20 난트퀘스트, 인크. Cd19-car 발현 nk 세포에 의한 cd19-양성 림프성 악성종양의 제거(elimination of cd19-positive lymphoid malignancies by cd19-car expressing nk cells)
EP3743513A4 (en) 2018-11-06 2021-11-24 Nantkwest, Inc. NK-92 CELLS MODIFIED BY CHIMERIC ANTIGEN RECEPTOR
US12109238B2 (en) * 2018-11-06 2024-10-08 Immunitybio, Inc. Chimeric antigen receptor-modified NK-92 cells
AU2019388876A1 (en) * 2018-11-26 2021-05-20 Immunitybio, Inc. IL-2 Dependent NK-92 cells with stable Fc receptor expression
CN113226340A (zh) 2018-11-26 2021-08-06 恩卡尔塔公司 同时扩增多种免疫细胞类型的方法、相关组合物及其在癌症免疫疗法中的用途
KR20210137085A (ko) 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
WO2020205100A1 (en) * 2019-03-15 2020-10-08 Nantcell, Inc. Recombinant eril-15 nk cells
AU2020279240A1 (en) 2019-05-20 2021-12-23 Pandion Operations, Inc. MAdCAM targeted immunotolerance
US20220265716A1 (en) * 2019-07-26 2022-08-25 Nantkwest, Inc. Antibody pre-loaded cd16+nk-92 cells as an effective therapeutic product for tumor lysis
IL283568B2 (en) * 2019-08-01 2025-01-01 Immunitybio Inc NK–92 cells modified with a chimeric antigen receptor against B7–H4
KR20210033436A (ko) * 2019-09-18 2021-03-26 주식회사 에스엘바이젠 신규 키메라 항원 수용체 암호화 유전자가 형질도입된 유전자 변형 nk 세포주 및 그의 용도
US20210106619A1 (en) * 2019-10-10 2021-04-15 Nantkwest, Inc. NK-92 Bone and Brain targeting
EP4061385A4 (en) * 2019-11-19 2024-08-14 Acibadem Mehmet Ali Aydinlar Üniversitesi METHOD FOR REDESIGNING AND EXPANDING NK92 CELLS FOR USE IN IMMUNOTHERAPY
AU2020387167B2 (en) * 2019-11-20 2024-10-24 Immunitybio, Inc. Cell-mediated transient delivery of immune-enhancing molecules into the tumor microenvironment
WO2021116913A1 (en) 2019-12-09 2021-06-17 Nantkwest, Inc. Screening of cell clones expressing polygenic transgenes through non-antibiotic dependent positive selection
US11230699B2 (en) 2020-01-28 2022-01-25 Immunitybio, Inc. Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors
WO2021154218A1 (en) 2020-01-28 2021-08-05 Nantkwest, Inc. Chimeric antigen receptor-modified nk-92 cells targeting egfr super-family receptors
EP4097220A4 (en) * 2020-01-30 2024-03-20 ImmunityBio, Inc. ELIMINATION OF BCMA-POSITIVE MALIGNANCIES BY CAR-EXPRESSING NK CELLS
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
JP7773789B2 (ja) * 2020-03-28 2025-11-20 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 癌の治療のための細胞免疫療法
KR102594083B1 (ko) 2020-07-07 2023-10-25 칸큐어 엘엘씨 Mic 항체 및 결합제 및 이의 사용 방법
AU2021372458A1 (en) * 2020-10-26 2023-06-15 Research Institute At Nationwide Children's Hospital Chimeric antigen receptor (car) nk cells and uses thereof
US11459372B2 (en) 2020-11-30 2022-10-04 Crispr Therapeutics Ag Gene-edited natural killer cells
EP4271798A1 (en) 2020-12-30 2023-11-08 CRISPR Therapeutics AG Compositions and methods for differentiating stem cells into nk cells
WO2024236557A1 (en) 2023-05-12 2024-11-21 Gilboa Therapeutics LTD Compositions comprising an fc domain for the treatment of medical conditions
EP4739323A1 (en) 2023-07-05 2026-05-13 ImmunityBio, Inc. <smallcaps/>? ? ?ex vivo? ? ? ? ?generation of immune effector cells from apheresis material intermediates
WO2025158400A1 (en) * 2024-01-24 2025-07-31 Yale University Compositions and methods of natural killer cell hyperboosts for enhancement of nk cell therapy

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69834257T2 (de) 1997-04-30 2007-01-04 Klingemann, Hans Natürliche killerzelllinien und verfahren zu ihrer verwendung
US8034332B2 (en) 1997-04-30 2011-10-11 Conkwest, Inc. Interleukin-secreting natural killer cell lines and methods of use
WO1999024566A1 (en) 1997-11-06 1999-05-20 Roche Diagnostics Gmbh Tumor-specific antigens, methods for their production and their use for immunization and diagnosis
WO2000020460A1 (en) 1998-10-05 2000-04-13 Ludwig Institute For Cancer Research Methods for producing human tumor antigen specific antibodies
US7098008B2 (en) 2000-04-25 2006-08-29 Ic&G Do. Ltd. Selected primers for detection of MAGE or GAGE genes for diagnosis of cancer and methods of use
SE526227C2 (sv) * 2002-05-15 2005-08-02 North China Pharmaceutical Group Metod för rening av rekombinant humant serumalbumin
CA2487932A1 (en) 2002-05-30 2003-12-11 Macrogenics, Inc. Cd16a binding proteins and use for the treatment of immune disorders
JP2008505071A (ja) * 2004-07-02 2008-02-21 アヴァリス・アクチエボラーグ 細胞を遺伝学的に活性化する方法、および、該細胞の使用
ES2678094T3 (es) 2004-07-10 2018-08-08 Fox Chase Cancer Center Líneas de células asesinas naturales genéticamente modificadas
EP2123754B1 (en) * 2007-01-30 2011-04-06 Forerunner Pharma Research Co., Ltd. CHIMERIC Fc GAMMA RECEPTOR AND METHOD FOR DETERMINATION OF ADCC ACTIVITY BY USING THE RECEPTOR
EP2161339A1 (en) * 2008-08-29 2010-03-10 F. Hoffmann-La Roche Ag ADCC with modified NK92 cells
CA2803391C (en) 2010-06-22 2021-11-09 Neogenix Oncology, Inc. Npc1 antibodies that bind a muc5ac epitope
EP3115373B1 (en) 2010-09-08 2019-08-28 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Chimeric antigen receptors with an optimized hinge region
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
JP6053688B2 (ja) 2011-10-07 2016-12-27 国立大学法人三重大学 キメラ抗原受容体
JP6267644B2 (ja) 2011-10-20 2018-01-24 アメリカ合衆国 抗ｃｄ２２キメラ抗原受容体
CN103483452B (zh) * 2012-06-12 2021-08-13 上海细胞治疗集团有限公司 双信号独立的嵌合抗原受体及其用途
AU2013312838B2 (en) 2012-09-04 2018-11-29 Cellectis Multi-chain chimeric antigen receptor and uses thereof
RU2729401C2 (ru) * 2012-10-02 2020-08-06 Мемориал Слоан-Кеттеринг Кэнсер Сентер Композиции и способы для иммунотерапии
US20150329640A1 (en) 2012-12-20 2015-11-19 Bluebird Bio, Inc. Chimeric antigen receptors and immune cells targeting b cell malignancies
US20160015749A1 (en) 2013-03-05 2016-01-21 Baylor College Of Medicine Engager cells for immunotherapy
ES2769574T3 (es) * 2013-03-15 2020-06-26 Michael C Milone Reconocimiento de células citotóxicas con receptores quiméricos para inmunoterapia adoptiva
DK2992020T3 (da) * 2013-05-03 2020-02-10 Ohio State Innovation Foundation Cs1-specifik kimær antigenreceptor-manipulerede immuneffektorceller
CN104561069A (zh) * 2013-10-23 2015-04-29 深圳先进技术研究院 含重组嵌合抗原受体基因表达盒的微环dna重组母质粒、含该表达盒的微环dna及应用
EP3701957B1 (en) * 2013-11-01 2022-12-28 ImmunityBio, Inc. Tumoricidal and antimicrobial compositions and methods
EP3858379A1 (en) * 2013-11-21 2021-08-04 Autolus Limited Cell
ES2958720T3 (es) * 2015-06-10 2024-02-13 Immunitybio Inc Células NK-92 modificadas para tratar el cáncer
KR20200119892A (ko) * 2018-10-31 2020-10-20 난트퀘스트, 인크. Cd19-car 발현 nk 세포에 의한 cd19-양성 림프성 악성종양의 제거(elimination of cd19-positive lymphoid malignancies by cd19-car expressing nk cells)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BOISSEL LAURENT ET AL, "Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity.", ONCOIMMUNOLOGY 01 OCT 2013, (2013-10-01), vol. 2, page e26527 *

Also Published As

Publication number Publication date
IL255884B1 (en) 2024-01-01
AU2016275030A1 (en) 2017-12-14
JP7275178B2 (ja) 2023-05-17
CA2987290A1 (en) 2016-12-15
EP4272757A3 (en) 2023-12-27
US20240002802A1 (en) 2024-01-04
CA2987290C (en) 2023-10-03
IL255884B2 (en) 2024-05-01
EP3307876B1 (en) 2023-09-13
EP4272757A2 (en) 2023-11-08
EP4424326A2 (en) 2024-09-04
CN113502270A (zh) 2021-10-15
KR20230062879A (ko) 2023-05-09
WO2016201304A1 (en) 2016-12-15
IL328383A (en) 2026-07-01
JP2021097694A (ja) 2021-07-01
JP2018517415A (ja) 2018-07-05
US20180163176A1 (en) 2018-06-14
CN107709552A (zh) 2018-02-16
KR102526538B1 (ko) 2023-04-28
IL309167B1 (en) 2026-06-01
KR20240013282A (ko) 2024-01-30
KR20250027585A (ko) 2025-02-26
JP2023054220A (ja) 2023-04-13
JP7836780B2 (ja) 2026-03-27
KR102627811B1 (ko) 2024-01-24
CN107709552B (zh) 2022-05-13
ES2958720T3 (es) 2024-02-13
US10738279B2 (en) 2020-08-11
US11788059B2 (en) 2023-10-17
US20210054337A1 (en) 2021-02-25
JP2025089426A (ja) 2025-06-12
EP3307876A4 (en) 2019-04-03
CN113502270B (zh) 2024-06-18
EP4424326A3 (en) 2024-11-13
EP3307876A1 (en) 2018-04-18
KR20180008862A (ko) 2018-01-24
IL309167A (en) 2024-02-01
IL255884A (en) 2018-01-31

Similar Documents

Publication Publication Date Title
US20240002802A1 (en) Modified nk-92 cells for treating cancer
KR101890638B1 (ko) Car 발현 벡터 및 car 발현 t 세포
AU2019375375A1 (en) Chimeric antigen receptor-modified NK-92 cells
CA3094111A1 (en) Elimination of pd-l1-positive malignancies by pd-l1 chimeric antigen receptor-expressing nk cells
CA3091224A1 (en) Use of cd33car modified high affinity nk cells (t-hank) to reduce myeloid-derived suppressor cells suppressor activity (or reduce negative impact on nk cell activity)
US20210187024A1 (en) NK-92 Cells to Stimulate Anti-Cancer Vaccine
CA3117936A1 (en) Il-2 dependent nk-92 cells with stable fc receptor expression
US20240366972A1 (en) Chimeric Antigen Receptor-Modified NK-92 Cells
US20210040451A1 (en) Use of 5% human albumin in wash and harvest media
CA3098471C (en) Optimization of nk-92 cell growth using poloxamer
HK1251016B (en) Modified nk-92 cells for treating cancer
HK1251016A1 (en) Modified nk-92 cells for treating cancer
HK40119596A (en) Chimeric antigen receptor-modified nk-92 cells

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: IMMUNITYBIO, INC.

Free format text: FORMER NAME(S): NANTKWEST, INC.